demonstrated improved rates of pCR and 2-year EFS regardless of PD-L1 expression with neoadjuvant chemoimmunotherapy compared with neoadjuvant chemotherapy alone, as well as an apparent trend that higher PD-L1 expression was associated with increased rates of 2-year EFS compared with lower PD-L1 expression ( 70 ).
← all excerpts
Unlocking the potential of immunotherapy for patients with resectable non-small cell lung cancer.
1
—
—